Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmuta...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Rivas, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marcos, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Lukas, Schuh, Anna, Eyre, Toby A., Kennedy, Ben, Bowles, Kris M., Vignetti, Marco, de la Serna, Javier, Moreno, Carol, Foà, Robin, Ghia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029555/
https://www.ncbi.nlm.nih.gov/pubmed/29674504
http://dx.doi.org/10.3324/haematol.2018.189837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029555/
https://www.ncbi.nlm.nih.gov/pubmed/29674504
http://dx.doi.org/10.3324/haematol.2018.189837

Ejemplares similares